BioNTech SE (BNTX) Q2 2026 Earnings Report

The call balances meaningful near‑term financial headwinds (sharp Q2 revenue decline, guidance reduction, increased SG&A and some timeline pushes) against substantial clinical and strategic progress: multiple encouraging Phase II signals (pumitamig, gotistobart), initiation of a Phase III for LCD, continued advancement of mRNA oncology programs, a strong cash position (EUR 16.6B) and active capital return. The pipeline momentum and capital strength mitigate short‑term revenue weakness, but the quarter highlights both execution progress and clear near‑term commercial challenges.

BioNTech revised its full‑year 2026 guidance to revenues of EUR 1.6–1.9 billion, adjusted R&D expenses of EUR 2.0–2.3 billion and adjusted SG&A unchanged at EUR 700–800 million. In Q2 the company reported revenues of EUR 106 million (vs. EUR 261 million a year ago) and H1 revenues of EUR 224 million; Q2 adjusted R&D was EUR 477 million (vs. EUR 509 million) and H1 adjusted R&D was EUR 1,004 million; Q2 adjusted SG&A was EUR 198 million (vs. EUR 137 million) and H1 adjusted SG&A was EUR 349 million. BioNTech ended the quarter with EUR 16.6 billion in cash, cash equivalents and securities (vs. EUR 16.0 billion a year earlier), is executing an up to $1 billion share repurchase program (USD 152 million repurchased so far), expects to recognize a EUR 613 million BMS collaboration payment largely in Q3, and cited a roughly EUR 400 million midpoint guidance reduction driven ~80% by softer COVID vaccine demand (with the remainder from milestone timing and other event‑driven items); near‑term results also reflect impairments and restructuring costs related to manufacturing footprint consolidation.